<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20130521//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Oral Maxillofac Res</journal-id>
<journal-id journal-id-type="publisher-id">JORM</journal-id>
<journal-title-group>
<journal-title>Journal of Oral &amp; Maxillofacial Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2029-283X</issn>
<publisher>
<publisher-name>Stilus Optimus</publisher-name>
<publisher-loc>Kaunas, Lithuania</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">v12n1e3ht</article-id>
<article-id pub-id-type="doi">10.5037/jomr.2021.12103</article-id>

<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>PTEN and α-SMA Expression and Diagnostic Role in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma with Concomitant Oral Submucous Fibrosis</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author" id="contrib1">
<name>
<surname>Monteiro</surname>
<given-names>Roshni</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" id="contrib2" corresp="yes">
<name>
<surname>Hallikeri</surname>
<given-names>Kaveri</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" id="contrib3">
<name>
<surname>Sudhakaran</surname>
<given-names>Archana</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
</contrib-group>

<aff id="aff1" rid="aff1">
<sup>1</sup>
<institution>Department of Oral and Maxillofacial Pathology and Oral Microbiology, SDM College of Dental Sciences and Hospital, Dharwad</institution><country>India.</country>
</aff>

<author-notes>
<corresp>Kaveri Hallikeri, 
<institution>Department of Oral and Maxillofacial Pathology and Oral Microbiology</institution>
<institution>SDM College of Dental Sciences and Hospital</institution>
<institution>A constituent unit of Shri Dharmasthala Manjunatheshwara University</institution>
<addr-line>Sattur, Dharwad-580009, Karnataka</addr-line>
<country>India</country>
<phone>+91 9620657979</phone><email>drcauveri2005@gmail.com</email>
</corresp>
</author-notes>

<pub-date pub-type="collection">
<season>Jan-Mar</season>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>3</month>
<year>2021</year>
</pub-date>
<volume>12</volume>
<issue>1</issue>
<elocation-id>e3</elocation-id>
<history>
<date date-type="received">
<day>2</day>
<month>12</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>3</month>
<year>2021</year>
</date>
</history>
<permissions>

<copyright-statement>Copyright &#169; Monteiro R, Hallikeri K, Sudhakaran A. Published in the JOURNAL OF ORAL &amp; MAXILLOFACIAL RESEARCH (http://www.ejomr.org), 31 March 2021.
</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
<license-p>
This is an open-access article, first published in the JOURNAL OF ORAL &amp; MAXILLOFACIAL RESEARCH, distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 UnportedLicense (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work and is properly cited. The copyright, license information and link to the original publication on (http://www.ejomr.org) must be included.</license-p>
</license>
</permissions>

<self-uri xlink:href="http://www.ejomr.org/JOMR/archives/2021/1/e3/v12n1e3ht.htm" xlink:type="simple"/>


<abstract>
<title>ABSTRACT</title>
<sec sec-type="objectives">
<title>Objectives</title>
<p>The diagnostic role and correlation between phosphatase and tensin homologue and alpha-smooth muscle actin in oral submucous fibrosis and oral squamous cell carcinoma with concomitant oral submucous fibrosis was analysed by this case control study. The mechanism by which phosphatase and tensin homologue controls myofibroblast expression was also evaluated.</p>
</sec>
<sec sec-type="material and methods">
<title>Material and Methods</title>
<p>Overall, 10 normal mucosa, 30 oral submucous fibrosis (OSF) and 30 oral squamous cell carcinoma (OSCC) with OSF were stained immunohistochemically with phosphatase and tensin homologue (PTEN) and alpha-smooth muscle actin (α-SMA). Percentage positivity, pattern of expression was statistically compared using Pearson’s Chi-square and Fischer exact tests. The correlation between markers was analysed using Spearman correlation.</p>
</sec>
<sec sec-type="results">
<title>Results</title>
<p>OSF and OSCC affected males predominantly with majority below 40 years and above 40 years of age respectively. Percentage of PTEN positive cells was statistically significant with gender (P = 0.024) and α-SMA distribution of pattern showed a significant correlation with habits (P = 0.018). A significant decrease in nuclear PTEN positivity (P &lt; 0.001) and a gradual increase in α-SMA cytoplasmic expression was noted from NM to OSF and OSCC. A statistically significant weak inverse correlation existed between PTEN and α-SMA.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>A reduced phosphatase and tensin homologue expression in oral submucous fibrosis makes it more prone for malignant transformation. An increase in stromal desmoplasia modifies differentiation, invasive and proliferative capacity of tumour cells. As phosphatase and tensin homologue functions through P-Akt pathway, P-Akt with phosphatase and tensin homologue could be a therapeutic target.</p>
</sec>
</abstract>

<kwd-group>
<kwd>immunohistochemistry</kwd>
<kwd>myofibroblast</kwd>
<kwd>oral cancer</kwd>
<kwd>oral submucous fibrosis</kwd>
<kwd>prognosis</kwd>
<kwd>tumor suppressor gene</kwd>
</kwd-group>
</article-meta>
</front>

<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>Oral potentially malignant disorders (OPMDs) are precursors of oral squamous cell carcinoma (OSCC). Thus prevention and early detection of OPMDs aids in decreasing the incidence and improves survival of those who could develop OSCC. Oral submucous fibrosis (OSF), a PMD has high prevalence in Indian subcontinent and South East Asia and is associated with chewing betel quid and commercially available areca nut preparations [<xref ref-type="bibr" rid="B1">1</xref>]. OSF is a chronic, insidious oral mucosal condition, characterized by juxtaepithelial inflammation and submucosal fibrosis induced by alkaloids (arecoline, arecaidine, guvacaine, guvacoline) and flavonoids in areca nut [<xref ref-type="bibr" rid="B2">2</xref>]. The younger population is mainly affected. A high malignant transformation rate ranging from 7 to 13%, and in India, ranging from 2.6 to 7.6% has been reported [<xref ref-type="bibr" rid="B1">1</xref>].</p>
<p>Tremendous efforts have been made to identify predictable diagnostic biomarkers like p53, β catenin, cyclin D1, Rb protein, Ki67 (MIB), bcl2, bax, c-met, alpha-smooth muscle actin (α-SMA), phosphatase and tensin homologue (PTEN), in OSF and their role in malignant transformation [<xref ref-type="bibr" rid="B3">3-5</xref>].</p>
<p>PTEN acts as a tumour suppressor gene and controller of myofibroblast differentiation by negatively regulating phosphatidyl inositol-3-kinase/AKT (PI3K/AKT) pathway in fibrotic disorders and malignancies of thyroid, kidney, lung, breast; endometrial precancer and also plays a role in immunity [<xref ref-type="bibr" rid="B6">6-11</xref>]. In OSF, like other fibrotic lesions, myoﬁbroblasts express α-SMA and are the primary producers of extracellular matrix (ECM) [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. An inverse correlation between PTEN and α-SMA expression has been noted in dermal fibrosis, idiopathic pulmonary fibrosis (IPF) and hepatic fibrosis [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B14">14-16</xref>].</p>
<p>The mechanism by which PTEN controls myofibroblast expression and the diagnostic role of PTEN and α-SMA in malignant transformation of OSF has not yet been studied. A better understanding of the relation between PTEN and α-SMA may help in unveiling their diagnostic and prognostic role in OSF and OSCC. Also the drugs targeting PI3K might have significant therapeutic activity in OSF and its malignant transformation. The presented retrospective case control study aimed at evaluating the phosphatase and tensin homologue mechanism controlling myofibroblast expression. Also analysed the diagnostic role and correlation between phosphatase and tensin homologue and alpha-smooth muscle actin in oral submucous fibrosis and oral squamous cell carcinoma with concomitant oral submucous fibrosis.</p>
</sec>

<sec sec-type="materials|methods">
<title>MATERIAL AND METHODS</title>
<p>The case control study was approved by the Institutional Review Board (IRB NO. IRB/2017/P/OP/55) of SDM College of Dental Sciences and Hospital, Dharwad, Karnataka, India. Following the approval, 70 formalin-fixed paraffin-embedded tissue blocks of OSF and OSCC with concomitant OSF having complete case details were selected randomly and retrieved from the archives of the Department of Oral Pathology and Microbiology, SDM College of Dental Sciences and Hospital. The study was conducted between January 2018 to June 2019. </p>
<p>The sample comprising of 70 cases was divided into three groups. The control group had 10 normal mucosa tissues from patients with no relevant habit history, with a healthy mucosa and without any systemic diseases or malignancies. The other two groups had 30 cases each of clinically and histologically (stained with haematoxylin and eosin) proven OSF and OSCC with concomitant OSF respectively. Clinical staging of OSF cases was done based on mouth opening according to Ranganathan et al. [<xref ref-type="bibr" rid="B17">17</xref>] and TNM staging was followed for OSCC with concomitant OSF [<xref ref-type="bibr" rid="B18">18</xref>]. Histopathologically, OSF was subdivided according to Roobans’ grading [<xref ref-type="bibr" rid="B19">19</xref>] and OSCC with concomitant OSF using Broders’ grading [<xref ref-type="bibr" rid="B20">20</xref>]. Patients with recurrence and those under treatment for oral carcinoma were excluded. The clinicopathological data of all cases were recorded and tabulated. </p>
<p>Tissue sections of 3 μm obtained from all cases on silane coated slides were subjected to immunohistochemical (IHC) analysis using PTEN protein rabbit monoclonal antibody (clone SP218, IgG immunoglobulin) and α-SMA mouse monoclonal antibody (clone 1A4, IgG2a immunoglobulin), and visualized by supersensitive polymer-HRP detection system (BioGenex Laboratories Inc.; San Ramon, California, USA); chromogen used was DAB (diaminobenzidine). Antigen heat retrieval was done using pressure cooker (0.1 M citrate buffer; pH 6). Standardized procedure according to the guidelines given by BioGenex Laboratories Inc. was followed. Brown precipitate in the nucleus and cytoplasm was considered to be a positive PTEN and α-SMA expression respectively.</p>
<p>The sections were examined at an ocular magnification of x10 and then a representative field (even staining) was chosen viewing at original magnification x40. Positive cells were counted from among 500 total tumour cells. </p>
<p>The following parameters were analysed:</p>
<list list-type="bullet" id="L1">
<list-item>
<p>Percentage of positive cells: 0 = no positive cells, 1 = 1 to 25%, 2 = 26 to 50%, 3 = &gt;50%.</p>
</list-item>
<list-item>
<p>Pattern of expression: 0 = absent, 1 = membrane, 2 = cytoplasm, 3 = membrane and cytoplasm, 4 = nuclear.</p>
</list-item>
<list-item>
<p>Expression in layers of mucosa: 0 = absent, 1 = basal/parabasal, 2 = spinous, 3 = superficial layer.</p>
</list-item>
</list>

<p><bold>Statistical analysis</bold></p>
<p>Non-parametric statistical analysis was done depending on the results by means of SPSS Statistics software, version 20.0 (IBM; New York, USA). Pearson’s Chi-square and Fischer exact tests were used to analyse the correlation between the clinicopathological parameters, compare the IHC expression of PTEN and α-SMA and to correlate the expression with the clinicopathological parameters. Statistical significance level was defined at P &lt; 0.05. Spearman correlation was used to find the correlation between the two markers. </p>
</sec>

<sec sec-type="results">
<title>RESULTS</title>
<p>The clinicopathological parameters of the study groups were assessed. Greater number of patients were below 40 years of age in OSF (73.3%), in contrast 63.3% cases of OSCC, were above the age of 40 years (P = 0.005). OSF group had all male patients (100%) and a male predilection was seen in OSCC (90%). </p>
<p>Chewing smokeless tobacco for more than 5 years was more prevalent among the groups (OSF = 93.3% and OSCC = 86.65%) than smoking. </p>
<p>Predominant site of involvement for OSCC was buccal mucosa (63.3%) followed by other sites- lip, alveolus (33.3%); tongue being the least affected (3.3%) (P &lt; 0.001).</p>
<p>In OSF, stage I and II were combined (26.6% cases), stage III and IV were combined (73.3% cases). Similarly, in OSCC, stage I and II were combined (90% cases), stage III and IV were combined (10% cases) (P &lt; 0.001).</p>
<p>Roobans histopathological grading of OSF showed most cases in the combined grade I and II (73.3%) followed by the combined grade III and IV (26.6%). The well and moderately differentiated OSCC had 76.6% and 23.3% cases respectively (P = 0.003).</p>
<p>In OSCC, depth of invasion (DOI) of tumour was grouped as &lt; 5 mm (30%), 5 to 10 mm (40%) and &gt; 10 mm (30%). Lymph node positivity was seen in 36.6% cases.</p>
<p>Statistical significant difference in the age, site, staging and grading among the study groups existed (<xref ref-type="table" rid="T1">Table 1</xref>).</p>

<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>
Clinicopathological data of groups using Pearson's Chi-square and Fisher exact test
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th  rowspan="3">
				Parameters
</th>
<th  rowspan="3">
				Category
</th>
<th>
				NM-10
</th>
<th>
				OSF-30
</th>
<th>
				OSCC + OSF-30
</th>
<th  rowspan="3">
				P-value
</th>
</tr>
<tr>
  <th colspan="3"><hr/></th>
  </tr>
<tr>
<th>
				N (%)
</th>
<th>
				N (%)
</th>
<th>
				N (%)
</th>
</tr>
</thead>
<tbody>
<tr>
<td  rowspan="3" align="center"><bold>
				Age</bold><break />
<bold>(years)
</bold></td>
<td align="center">
				&lt; 40
						  </td>
<td align="center">
				8 (80)
						  </td>
<td align="center">
				22 (73.3)
						  </td>
<td align="center">
				11 (36.6)
						  </td>
<td  rowspan="3" align="center">
				0.005<sup>b</sup>
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				≥ 40
</td>
<td align="center">
				2 (20)
						  </td>
<td align="center">
				8 (26.6)
						  </td>
<td align="center">
				19 (63.3)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				Sex
</bold></td>
<td align="center">
				Male
						  </td>
<td align="center">
				8 (80)
						  </td>
<td align="center">
				30 (100)
						  </td>
<td align="center">
				27 (90)
						  </td>
<td  rowspan="3" align="center">
				0.72
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Female
</td>
<td align="center">
				2 (20)
						  </td>
<td align="center">
				0
						  </td>
<td align="center">
				3 (10)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				Habits
</bold></td>
<td align="center">
				Chewing
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				28 (93.3)
						  </td>
<td align="center">
				26 (86.6)
						  </td>
<td  rowspan="3" align="center">
				0.548
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Mixed
</td>
<td align="center">
				-
						  </td>
<td align="center">
				2 (6.7)
						  </td>
<td align="center">
				2 (6.6)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				Frequency
</bold></td>
<td align="center">
				&lt; 5 times
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				17 (56.6)
						  </td>
<td align="center">
				20 (66.6)
						  </td>
<td  rowspan="3" align="center">
				0.426
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				≥ 5 times
</td>
<td align="center">
				-
						  </td>
<td align="center">
				13 (43.3)
						  </td>
<td align="center">
				10 (33.3)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				Duration
</bold></td>
<td align="center">
				&lt; 5 years
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				14 (46.6)
						  </td>
<td align="center">
				11 (36.6)
						  </td>
<td  rowspan="3" align="center">
				0.432
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				≥ 5 years
</td>
<td align="center">
				-
						  </td>
<td align="center">
				16 (53.3)
						  </td>
<td align="center">
				19 (63.3)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				Site
</bold></td>
<td align="center">
				Buccal mucosa
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				19 (63.3)
						  </td>
<td  rowspan="3" align="center">
				&lt; 0.001<sup>b</sup>
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Others
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				10 (33.3)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				OSF staging
</bold></td>
<td align="center">
				Stage I and II
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				9 (30)
						  </td>
<td align="center">
				-
						  </td>
<td  rowspan="3" align="center">
				0.11
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Stage III and IV
</td>
<td align="center">
				-
						  </td>
<td align="center">
				21 (70)
						  </td>
<td align="center">
				-
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				OSF grading
</bold></td>
<td align="center">
				Stage I and II
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				22 (73.3)
						  </td>
<td align="center">
				-
						  </td>
<td  rowspan="3" align="center">
				&lt; 0.001<sup>b</sup>
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Stage III and IV
</td>
<td align="center">
				-
						  </td>
<td align="center">
				8 (26.6)
						  </td>
<td align="center">
				-
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				OSCC staging
</bold></td>
<td align="center">
				Stage I and II
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				27 (90)
						  </td>
<td  rowspan="3" align="center">
				0.028<sup>a</sup>
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Stage III and IV
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				3 (10)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				OSCC grading
</bold></td>
<td align="center">
				Well diff
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				23 (76.6)
						  </td>
<td  rowspan="3" align="center">
				0.003<sup>b</sup>
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Moderately diff
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				7 (23.3)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="5" align="center"><bold>
				DOI
</bold></td>
<td align="center">
				&lt; 5 mm
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				9 (30)
						  </td>
<td  rowspan="5" align="center">
				0.741
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				5 to 10 mm
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				12 (40)
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				&gt; 10 mm
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				9 (30)
</td>
</tr>
<tr>
  <td colspan="6" align="center"><hr/></td>
  </tr>
<tr>
<td  rowspan="3" align="center"><bold>
				Lymph node
</bold></td>
<td align="center">
				Positive
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				11 (36.6)
						  </td>
<td  rowspan="3" align="center">
				0.144
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Negative
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				19 (63.3)
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<sup>a</sup>Statistically significant at level P &lt; 0.05, Pearson's Chi-square and at level P &lt; 0.05, Fischer exact test.
</p>
<p>
<sup>b</sup>Statistically highly significant at level P &lt; 0.05, Pearson's Chi-square and at level P &lt; 0.05, Fischer exact test.
</p>
<p>
NM = normal mucosa; OSF = oral submucous fibrosis; OSCC = oral squamous cell carcinoma; N = number.
</p>
</fn>
</table-wrap-foot>
</table-wrap>

<p>Percentage of PTEN positive cells was statistically significant with gender (P = 0.024) and α-SMA distribution of pattern showed a significant correlation with habits (P = 0.018). A significant decrease in nuclear PTEN positivity (P &lt; 0.001) and gradual increase in α-SMA cytoplasmic expression was noted from normal mucosa to OSF and OSCC. A statistically significant weak inverse correlation existed between PTEN and α-SMA.</p>
<p>PTEN nuclear expression was seen in basal and parabasal layers of normal and OSF epithelium (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and in OSCC, in the peripheral cells of tumour islands (<xref ref-type="fig" rid="fig2">Figure 2</xref>) (P = 0.233). In the normal mucosa, 1 to 25% positive cells were seen in 40% and 26 to 50% in 50% of tissues, while in OSF, 66.6% and in OSCC, 30% had 1 to 25% positive cells (P &lt; 0.001). Thus a reduction in the expression was noted i.e., 33.3% OSF cases and 70% OSCC cases failed to show any expression. This difference was statistically significant (P = 0.001) (<xref ref-type="table" rid="T2">Table 2</xref>).</p>

  <fig id="fig1">
  <label>Figure 1</label>
  <caption>
  <p>
Nuclear phosphatase and tensin homologue staining in basal and parabasal layers.
  </p><p>
A = normal mucosa (original magnification x20).
  </p><p>
B = oral submucous fibrosis (original magnification x40).
  </p>
  </caption>
  <graphic xlink:href="jomr-12-e3-g001.tiff"/>
  </fig>

  <fig id="fig2">
  <label>Figure 2</label>
  <caption>
  <p>
Phosphatase and tensin homologue (PTEN) nuclear staining.
  </p><p>
A = Intense PTEN staining in tumour islands of oral squamous cell carcinoma (OSCC) with concomitant oral submucous fibrosis (OSF) (original magnification x20).
  </p><p>
B = Intense nuclear PTEN staining in tumour cells of OSCC with concomitant OSF (original magnification x40).
  </p>
  </caption>
  <graphic xlink:href="jomr-12-e3-g002.tiff"/>
  </fig>

<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>
Comparison of IHC expression of PTEN among groups using Pearson's Chi-square and Fisher exact test
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th  rowspan="3">
				Parameters
    </th>
<th  rowspan="3">
				Category
    </th>
<th>
				NM
    </th>
<th>
				OSF
    </th>
<th>
				OSF + OSCC
    </th>
<th  rowspan="3">
				P-value
						  </th>
</tr>
<tr>
  <th colspan="3"><hr/></th>
  </tr>
<tr>
<th>
				N (%)
    </th>
<th>
				N (%)
    </th>
<th>
				N (%)
						  </th>
</tr>
</thead>
<tbody>
<tr>
<td  rowspan="7" align="left"><bold>
				Percentage</bold><break /><bold>positivity
</bold></td>
<td align="center">
				0 = no positive cells
						  </td>
<td align="center">
				1 (10)
				      </td>
<td align="center">
				10 (33.3)
			        </td>
<td align="center">
				21 (70)
		          </td>
<td  rowspan="7" align="center">
				&lt; 0.001<sup>a</sup>
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				1 = 0 to 25%
					    </td>
<td align="center">
				4 (40)
				      </td>
<td align="center">
				20 (66.6)
			        </td>
<td align="center">
				9 (30)
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				2 = 26 to 50%
				      </td>
<td align="center">
				5 (50)
			        </td>
<td align="center">
				-
		          </td>
<td align="center">
				-
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				3 = &gt; 50%
			        </td>
<td align="center">
				-
		          </td>
<td align="center">
				-
	            </td>
<td align="center">
				-
						  </td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td  rowspan="5" align="left"><bold>
				Pattern
	                      </bold></td>
<td align="center">
				Absent
	            </td>
<td align="center">
				1 (10)
              </td>
<td align="center">
				10 (33.3)
            </td>
<td align="center">
				21 (70)
          </td>
<td  rowspan="5" align="center">
				0.001<sup>a</sup>
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Cytoplasm
	            </td>
<td align="center">
				-
              </td>
<td align="center">
				-
            </td>
<td align="center">
				-
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Nuclear
              </td>
<td align="center">
				9 (90)
            </td>
<td align="center">
				20 (66.6)
          </td>
<td align="center">
				9 (30)
						  </td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td  rowspan="7" align="left"><bold>
				Layers
                          </bold></td>
<td align="center">
				0 = absent
          </td>
<td align="center">
				1 (10)
        </td>
<td align="center">
				10 (33.3)
      </td>
<td align="center">
				-
    </td>
<td  rowspan="7" align="center">
				0.233
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				1 = basal/parabasal
          </td>
<td align="center">
				9 (90)
        </td>
<td align="center">
				20 (66.6)
      </td>
<td align="center">
				-
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				2 = spinous
        </td>
<td align="center">
				-
      </td>
<td align="center">
				-
    </td>
<td align="center">
				-
						  </td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				3 = superficial layer
      </td>
<td align="center">
				-
    </td>
<td align="center">
				-
  </td>
<td align="center">
				-
						  </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
Comparison of IHC expression of PTEN among groups using Pearson's Chi-square and Fisher exact test
</p>
<p>
<sup>a</sup>Statistically significant at level P &lt; 0.05, Pearson's Chi-square and at level P &lt; 0.05, Fischer exact test.
</p>
<p>
NM = normal mucosa; OSF = oral submucous fibrosis; OSCC = oral squamous cell carcinoma; N = number; IHC = immunohistochemical; PTEN = phosphatase and tensin homologue.
</p>
</fn>
</table-wrap-foot>
</table-wrap>

<p>In case of α-SMA, cytoplasmic positivity was seen in 30% of NM, 53.3% of OSF (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and 56.6% of OSCC (<xref ref-type="fig" rid="fig4">Figure 4</xref>). There was no statistically significant difference among the study groups. </p>

  <fig id="fig3">
  <label>Figure 3</label>
  <caption>
  <p>
Alpha-smooth muscle actin staining around the vessel walls taken as internal control and in the myofibroblast cytoplasm in the connective tissue stroma of oral submucous fibrosis (original magnification x40).
  </p>
  </caption>
  <graphic xlink:href="jomr-12-e3-g003.tiff"/>
  </fig>

  <fig id="fig4">
  <label>Figure 4</label>
  <caption>
  <p>
Cytoplasmic alpha-smooth muscle actin staining myofibroblasts in the connective tissue stroma of oral squamous cell carcinoma: A = original magnification x20; B = original magnification x40.
  </p>
  </caption>
  <graphic xlink:href="jomr-12-e3-g004.tiff"/>
  </fig>

<p>Comparison of percentage of positive cells of PTEN with the clinicopathological parameters showed a statistical significant difference for gender (P = 0.024). Distribution of pattern of PTEN showed no statistically significant difference for any of the clinicopathological parameters (<xref ref-type="table" rid="T3">Table 3</xref>).</p>

<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>
Comparison of IHC expression of α-SMA among groups using Pearson Chi-square and Fisher exact test
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th  rowspan="3">
				Parameters
</th>
<th  rowspan="3">
				Category
</th>
<th>
				NM
</th>
<th>
				OSF
</th>
<th>
				OSF + OSCC
</th>
<th  rowspan="3">
				P-value
</th>
</tr>
<tr>
  <th colspan="3"><hr/></th>
  </tr>
<tr>
<th>
				N (%)
</th>
<th>
				N (%)
</th>
<th>
				N (%)
</th>
</tr>
</thead>
<tbody>
<tr>
<td  rowspan="7" align="left">
				              <bold>Percentage</bold><break />
			                <bold>positivity</bold></td>
<td align="center">
				0 = no positive cells
						  </td>
<td align="center">
				7 (70)
						  </td>
<td align="center">
				14 (46.6)
						  </td>
<td align="center">
				13 (43.3)
						  </td>
<td  rowspan="7" align="center">
				0.426
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				1 = 0 to 25%
</td>
<td align="center">
				3 (30)
						  </td>
<td align="center">
				16 (53.3)
						  </td>
<td align="center">
				15 (50)
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				2 = 26 to 50%
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				2 (6.6)
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				3 = &gt; 50%
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				-
</td>
</tr>
<tr>
  <td colspan="6" align="left"><hr/></td>
  </tr>
<tr>
<td  rowspan="5" align="left">
				              <bold>Pattern
						    </bold></td>
<td align="center">
				Absent
						  </td>
<td align="center">
				7 (70)
						  </td>
<td align="center">
				14 (46.6)
						  </td>
<td align="center">
				13 (43.3)
						  </td>
<td  rowspan="5" align="center">
				0.331
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Cytoplasm
</td>
<td align="center">
				3 (30)
						  </td>
<td align="center">
				16 (53.3)
						  </td>
<td align="center">
				17 (56.6)
</td>
</tr>
<tr>
  <td colspan="4" align="center"><hr/></td>
  </tr>
<tr>
<td align="center">
				Nuclear
</td>
<td align="center">
				-
						  </td>
<td align="center">
				-
						  </td>
<td align="center">
				-
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
NM = normal mucosa; OSF = oral submucous fibrosis; OSCC = oral squamous cell carcinoma; N = number; IHC = immunohistochemical; α-SMA = alpha- smooth muscle actin.
</p>
</fn>
</table-wrap-foot>
</table-wrap>

<p>Percentage positivity of α-SMA showed no statistically significant difference for clinicopathological parameters, but distribution of pattern of α-SMA showed a significant correlation with habits.</p>
<p>Comparison of percentage positivity of PTEN and α-SMA showed no statistical significant difference in OSF and OSCC groups, while the distribution of pattern of PTEN and α-SMA had a high statistical significant difference in all three study groups (P &lt; 0.001) (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p>

  <fig id="fig5">
  <label>Figure 5</label>
  <caption>
  <p>
A = comparison of percentage positivity of phosphatase and tensin homologue and alpha-smooth muscle actin.
  </p><p>
B = comparison of distribution of pattern of phosphatase and tensin homologue and alpha-smooth muscle actin.
  </p>
  </caption>
  <graphic xlink:href="jomr-12-e3-g005.tiff"/>
  </fig>

<p>Spearman correlation between PTEN and α-SMA among study groups showed a statistically significant weak inverse correlation (P = 0.012)</p>
</sec>

<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>PTEN, on chromosome 10q23 is “the most highly mutated gene in the post p53 era”, encoding a protein which dephosphorylates both protein and lipid substrates and negatively regulates the PI3K/AKT pathway [<xref ref-type="bibr" rid="B21">21-23</xref>]. Normally, the lipid phosphatase dephosphorylates PIP3, opposing PI3K and inhibits activation of the downstream pathway [<xref ref-type="bibr" rid="B24">24</xref>]. The dephosphorylation inactivates substrates making it a tumour suppressor gene. PTEN inactivation leads to PI3K/AKT activation and phosphorylation of PIP2 in the 3’ position of the inositol ring at the cell membrane leading to PIP3 synthesis and initiation of G1 phase of cell cycle and reduction in apoptosis, thereby predisposing to the development of cancer [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. PTEN has been studied in precancers of endometrium, leukoplakia; cancers of breast, prostate, endometrium and head and neck [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. PTEN also negatively regulates cell survival and fibroblast proliferation in the pathogenesis of fibrotic disorders like OSF, lung fibrosis, dermal fibrosis, hepatic fibrosis [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B21">21</xref>].</p>
<p>The clinicopathological parameters in relation to OSF in the present study were in accordance with that of previous studies where predominantly males in the second and third decades of life with the habit of chewing ghutka and other commercially available areca nut preparations for more than 10 years were affected by OSF; with the severity related to frequency and duration of habit [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. OSCC concomitant with OSF, in contrast to our study has been reported to affect males below 50 years of age while OSCC without OSF in patients above 50 years of age, probably because patients suffering from OSCC without concomitant OSF do not normally experience pain and discomfort till the lesion progresses to a functionally restrictive stage [<xref ref-type="bibr" rid="B28">28-30</xref>]. Likewise, males with the habit of consuming commercially available areca nut preparations for more than 5 years have been reported to be at higher risk of OSCC with OSF [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. In OSCC with OSF, the fibrous stroma limiting tumour infiltration, accounts for better prognosis than in OSCC without OSF by means of tumour depth and differentiation. Also lymph node metastasis and extracapsular spread (ECS) is less in OSCC arising from OSF [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. However, controversy still exists regarding the prognosis of OSCC with and without OSF. </p>
<p>Apart from the clinicopathological aspect, oral carcinogenesis encompasses mutations and epigenetic abnormalities in the activation of oncogenes and inactivation of tumour suppressor genes that control cell growth, inhibit cell proliferation by inducing apoptosis and tumour development [<xref ref-type="bibr" rid="B31">31</xref>]. With this background, we undertook this study to know more about the molecular changes in the malignant transformation of OSF. Tumour suppressor genes p53, p16, retinoblastoma (RB), PTEN have been studied in OSF to assess their role in progression of cancer and prediction of malignant transformation [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. Likewise, we studied the expression of PTEN in normal mucosa, OSF and OSCC with concomitant OSF.</p>
<p>An intense nuclear PTEN staining seen in basal and parabasal layers in nearly all normal and OSF epithelium pointed out its normal function, but the percentage of positivity gradually reduced in OSF group, probably indicating the 33.3% OSF cases with loss of expression are more prone to malignant transformation. This was substantiated by the OSCC group exhibiting a further gradual decrease in the number of positive cells (i.e., 70% were negative), seen at the periphery of tumour islands. Angadi and Krishnapillai [<xref ref-type="bibr" rid="B21">21</xref>], have also reported an intense nuclear stain in basal and parabasal layers of normal and OSF epithelium that reduced progressively from OSF to OSCC with positive cells at the tumour island periphery. Nuclear PTEN maintains chromosomal stability through physical interaction with centromeres and control of DNA repair [<xref ref-type="bibr" rid="B34">34</xref>]. Contrastingly, Jasphin et al. [<xref ref-type="bibr" rid="B35">35</xref>] on assessing the expression of PTEN between grades of OSCC, noted positivity in the cell cytoplasm; predominantly in basal and spinous layers with intensity reducing towards the granular layer. However, in spite of a decrease in the cells staining for PTEN in OSCC compared to the normal tissues, no statistical significance was seen in expression among the grades.</p>
<p>While nuclear PTEN is more stable and retains the capability of inhibiting AKT and inducing cell death, it downregulates cyclin D1 and phospho-MAPK and is thus crucial for cell cycle arrest [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. Compared to cytoplasmic staining, nuclear staining of PTEN is more marked particularly in undifferentiated and metastatic tumours of thyroid and melanoma. But the role of this shift in cellular localization in tumour pathogenesis is yet to be understood [<xref ref-type="bibr" rid="B38">38</xref>].</p>
<p>An increase in PTEN expression predominantly in basal and parabasal cell cytoplasm in dysplasia may be considered an attempt to control the increased AKT expression. In leukoplakia, PTEN allelic loss is an important mechanism causing progression to oral cancer [<xref ref-type="bibr" rid="B25">25</xref>].</p>
<p>The expression and genetic alterations of PTEN in OSCC have shown the epigenetic changes to be related to a down regulation of the protein [<xref ref-type="bibr" rid="B39">39</xref>]. The homozygous deletion or point mutation may not play a crucial role in PTEN inactivation process of carcinomas of oral cavity [<xref ref-type="bibr" rid="B40">40</xref>]. Activation of AKT is known to be associated with advanced stages and poor prognosis in OSCC; and induced PTEN over-expression downregulates AKT phosphorylation and encourages apoptosis [<xref ref-type="bibr" rid="B35">35</xref>].</p>
<p>In malignancies of human brain, breast and prostate, PTEN mutations have been assessed [<xref ref-type="bibr" rid="B8">8</xref>]. Squarize et al. [<xref ref-type="bibr" rid="B24">24</xref>], found multiple HNSCC lesions in PTEN deficient mice. Mutter et al. [<xref ref-type="bibr" rid="B9">9</xref>], reported PTEN mutations in 83% of endometrial cancers and 55% of precancers; most had mutation in only one PTEN allele. Roa et al. [<xref ref-type="bibr" rid="B22">22</xref>], noted that patients with reduced PTEN expression died within 10 months indicating poor prognosis.</p>
<p>Functionally, PTEN controls/regulates p53 by preventing its degradation through PI3K signalling pathway [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. Inactivation of PI3K pathway, leads to decreased phosphorylation of mouse double minute 2 homolog (MDM2) by AKT and translocation of MDM2 to cytoplasm. Cytoplasmic MDM2 cannot ubiquitinate nuclear p53 and so p53 levels increase. Thus p53 increases PTEN levels and, conversely, PTEN increases p53 levels [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. Studies in mammary tumours and liposarcomas showed that p53 combined with PTEN might be an essential blockage in their development [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>].</p>
<p>In consort with tumour suppressor genes, the stroma comprising inflammatory cells, small vessels, fibroblasts, myofibroblasts, and ECM components is vital in controlling tumour growth and differentiation. Myofibroblasts, the key cellular mediators of fibrosis in OSF express α-SMA, produce collagen, ECM proteins and proteolytic enzymes causing matrix degradation and tumour invasion [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref>]. PTEN playing a role in embryogenesis, immunity, fibrosis and malignancy is known to have an inverse correlation with α-SMA [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. Thus PTEN acts both as a tumour suppressor and controller of myofibroblast.</p>
<p>PTEN gene inactivation results in TGF β1 induced disassembly of tight junction of epithelial cells, destruction of basement membrane and increased epithelial derived myofibroblast due to up-regulation of AKT/S6K/Snail pathway, playing a role in epithelial-mesenchymal transition (EMT) [<xref ref-type="bibr" rid="B14">14</xref>]. </p>
<p>According to Xie et al. [<xref ref-type="bibr" rid="B50">50</xref>], PTEN overexpression decreases signalling via the PI3K/AKT and TGF β/Smad3 pathways in IPF and inhibits TGF β1 mediated myofibroblast differentiation. An increased TGF β in OSF can reduce PTEN levels allowing for AKT activity and consequently prolonged survival of fibroblasts and increased ECM production and fibrosis [<xref ref-type="bibr" rid="B21">21</xref>]. Deletion of PTEN in mouse fibroblasts raises AKT phosphorylation and expression of connective tissue growth factor (CTGF/CCN2) and an escalation in dermal thickness owing to excess collagen deposition. An elevated selective inhibition of PI3K/AKT pathway reduces overexpression of collagen and CCN2. Thus, PTEN appears to be a potential regulator of fibrogenesis [<xref ref-type="bibr" rid="B6">6</xref>].</p>
<p>In the present study, an intense α-SMA staining in myofibroblast cytoplasm, relatively more in OSF and OSCC than in normal mucosa with gradual increase both from normal to OSF and OSF to OSCC was witnessed. But a statistical significance difference failed to exist. In OSF group, 12 cases were in the combined stage I and II, 4 were in the combined stage III and IV. Similar observations with an increase in number of α-SMA stained myofibroblasts in OSF compared to normal mucosa, but with a statistically significant increase in population between early and advanced stages have been reported, demonstrating that myofibroblasts could serve as effective prognostic markers for disease progression in OSF [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>].</p>
<p>Alka et al. [<xref ref-type="bibr" rid="B51">51</xref>], revealed high α-SMA expression in OSCC with and without OSF compared to OSF, which indicated despite the statistically insignificant difference, altered ECM in OSCC with OSF may perhaps be responsible for modified EMT. In OSCC not associated with OSF, expression of α-SMA is greater in OSCC than in OSF alone or OSF associated with dysplasia. The proteolytic enzymes secreted by activated myofibroblasts cause matrix degradation, contributing to cancer cell invasion and metastasis [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In OSCC arising from OSF, EMT occurs first when areca nut induced cell injury causes excessive collagen cross-linking in ECM; second when there is malignant transformation during which cytokines and growth factors released from cancer cells induce myofibroblast transdifferentiation [<xref ref-type="bibr" rid="B53">53</xref>].</p>
<p>A positive correlation between OSCC histological grades and myofibroblasts has not been established, suggesting formation and differentiation of myofibroblasts is induced somewhere in the invasive stage of OSCC, and an increase in severity and differentiation would not affect their number [<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. Also variation in TGF β secretion essential for myofibroblast differentiation by tumour cells could be a reason for the decrease in myofibroblasts [<xref ref-type="bibr" rid="B51">51</xref>].</p>
<p>We noted a gradual decrease in PTEN expression and a gradual increase in α-SMA expression from normal to OSF and OSCC, providing a weak inverse correlation between PTEN and α-SMA. In IPF, an inverse correlation between PTEN and α-SMA expression has been established and α-SMA is the hallmark of mature myofibroblasts [<xref ref-type="bibr" rid="B56">56</xref>,<xref ref-type="bibr" rid="B57">57</xref>]. Once fibrosis is established, there can be either persistence without significant progression of disease or eventual malignant transformation [<xref ref-type="bibr" rid="B52">52</xref>]. An increase in number of myofibroblast both in OSCC associated and not associated with OSF indicates a poor prognosis [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Thus PTEN controlling fibroblast differentiation into myofibroblast plays a definite role in carcinogenesis. However, the present study suffered from certain shortcomings. A larger sample size and a follow-up of the cases would certainly aid in knowing the response to the treatment and a better validation of the results. </p>
</sec>

<sec sec-type="conclusions">
<title>CONCLUSIONS</title>
<p>The presented study concludes the absence of phosphatase and tensin homologue positivity in oral submucous fibrosis suggests these cases have a greater tendency to progress towards malignancy. Thus phosphatase and tensin homologue plays a crucial role in tumorigenesis of oral squamous cell carcinoma. In addition, alpha-smooth muscle actin has an effective prognostic role in disease progression of oral submucous fibrosis. </p>
<p>The weak inverse correlation between phosphatase and tensin homologue and alpha-smooth muscle actin showed that phosphatase and tensin homologue aids in myofibroblast differentiation in oral submucous fibrosis, further increasing fibrosis and desmoplasia. </p>
<p>Thus alteration of phosphatase and tensin homologue and alpha-smooth muscle actin is likely an important molecular event in pathogenesis of oral submucous fibrosis and its malignant transformation. Since phosphatase and tensin homologue is involved in the PI3K/AKT pathway, drugs targeting PI3K itself might have significant therapeutic activity in phosphatase and tensin homologue null cancers. </p>
</sec>
</body>

<back>
<ack>
<sec sec-type="acknowledgments and disclosure statements">
<title>ACKNOWLEDGMENTS AND DISCLOSURE STATEMENTS</title>
<p>The authors report no conflicts of interest related to this study.</p>
</sec>
</ack>

<ref-list>
<title>REFERENCES</title>
    <ref id="B1"><label>1</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Ray</surname>
<given-names>JG</given-names>
</name><name>
<surname>Ranganathan</surname>
<given-names>K</given-names>
</name><name>
<surname>Chattopadhyay</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>Malignant transformation of oral submucous fibrosis: overview of histopathological aspects. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Aug;122(2):200-9.</source>
<pub-id pub-id-type="pmid">27422418</pub-id>
<pub-id pub-id-type="doi">10.1016/j.oooo.2015.11.024</pub-id>
</element-citation>
    </ref>
    <ref id="B2"><label>2</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Angadi</surname>
<given-names>PV</given-names>
</name><name>
<surname>Rao</surname>
<given-names>SS</given-names>
</name>
</person-group>
<source>Areca nut in pathogenesis of oral submucous fibrosis: revisited. Oral Maxillofac Surg. 2011 Mar;15(1):1-9.</source>
<pub-id pub-id-type="pmid">20376683</pub-id>
<pub-id pub-id-type="doi">10.1007/s10006-010-0219-8</pub-id>
</element-citation>
    </ref>
    <ref id="B3"><label>3</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Bazarsad</surname>
<given-names>S</given-names>
</name><name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name><name>
<surname>Kim</surname>
<given-names>KY</given-names>
</name><name>
<surname>Illeperuma</surname>
<given-names>R</given-names>
</name><name>
<surname>Jayasinghe</surname>
<given-names>RD</given-names>
</name><name>
<surname>Tilakaratne</surname>
<given-names>WM</given-names>
</name><name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
</person-group>
<source>Identification of a combined biomarker for malignant transformation in oral submucous fibrosis. J Oral Pathol Med. 2017 Jul;46(6):431-438.</source>
<pub-id pub-id-type="pmid">27497264</pub-id>
<pub-id pub-id-type="pmcid">PMC 5516200</pub-id>
<pub-id pub-id-type="doi">10.1111/jop.12483</pub-id>
</element-citation>
    </ref>
    <ref id="B4"><label>4</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Ranganathan</surname>
<given-names>K</given-names>
</name><name>
<surname>Kavitha</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>Proliferation and apoptosis markers in oral submucous fibrosis. J Oral Maxillofac Pathol. 2011 May;15(2):148-53.</source>
<pub-id pub-id-type="pmid">22529572</pub-id>
<pub-id pub-id-type="pmcid">PMC 3329703</pub-id>
<pub-id pub-id-type="doi">10.4103/0973-029X.84478</pub-id>
</element-citation>
    </ref>
    <ref id="B5"><label>5</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Seifi</surname>
<given-names>S</given-names>
</name><name>
<surname>Shafaei</surname>
<given-names>S</given-names>
</name><name>
<surname>Shafigh</surname>
<given-names>E</given-names>
</name><name>
<surname>Sahabi</surname>
<given-names>SM</given-names>
</name><name>
<surname>Ghasemi</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>Myofibroblast stromal presence and distribution in squamous epithelial carcinomas, oral dysplasia and hyperkeratosis. Asian Pac J Cancer Prev. 2010;11(2):359-64.</source>
<pub-id pub-id-type="pmid">20843116</pub-id>
</element-citation>
    </ref>
    <ref id="B6"><label>6</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Parapuram</surname>
<given-names>SK</given-names>
</name><name>
<surname>Shi-wen</surname>
<given-names>X</given-names>
</name><name>
<surname>Elliott</surname>
<given-names>C</given-names>
</name><name>
<surname>Welch</surname>
<given-names>ID</given-names>
</name><name>
<surname>Jones</surname>
<given-names>H</given-names>
</name><name>
<surname>Baron</surname>
<given-names>M</given-names>
</name><name>
<surname>Denton</surname>
<given-names>CP</given-names>
</name><name>
<surname>Abraham</surname>
<given-names>DJ</given-names>
</name><name>
<surname>Leask</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol. 2011 Oct;131(10):1996-2003.</source>
<pub-id pub-id-type="pmid">21654839</pub-id>
<pub-id pub-id-type="doi">10.1038/jid.2011.156</pub-id>
</element-citation>
    </ref>
    <ref id="B7"><label>7</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Gimm</surname>
<given-names>O</given-names>
</name><name>
<surname>Perren</surname>
<given-names>A</given-names>
</name><name>
<surname>Weng</surname>
<given-names>LP</given-names>
</name><name>
<surname>Marsh</surname>
<given-names>DJ</given-names>
</name><name>
<surname>Yeh</surname>
<given-names>JJ</given-names>
</name><name>
<surname>Ziebold</surname>
<given-names>U</given-names>
</name><name>
<surname>Gil</surname>
<given-names>E</given-names>
</name><name>
<surname>Hinze</surname>
<given-names>R</given-names>
</name><name>
<surname>Delbridge</surname>
<given-names>L</given-names>
</name><name>
<surname>Lees</surname>
<given-names>JA</given-names>
</name><name>
<surname>Mutter</surname>
<given-names>GL</given-names>
</name><name>
<surname>Robinson</surname>
<given-names>BG</given-names>
</name><name>
<surname>Komminoth</surname>
<given-names>P</given-names>
</name><name>
<surname>Dralle</surname>
<given-names>H</given-names>
</name><name>
<surname>Eng</surname>
<given-names>C</given-names>
</name>
</person-group>
<source>Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000 May;156(5):1693-700.</source>
<pub-id pub-id-type="pmid">10793080</pub-id>
<pub-id pub-id-type="pmcid">PMC 1876937</pub-id>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)65040-7</pub-id>
</element-citation>
    </ref>
    <ref id="B8"><label>8</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Li</surname>
<given-names>J</given-names>
</name><name>
<surname>Yen</surname>
<given-names>C</given-names>
</name><name>
<surname>Liaw</surname>
<given-names>D</given-names>
</name><name>
<surname>Podsypanina</surname>
<given-names>K</given-names>
</name><name>
<surname>Bose</surname>
<given-names>S</given-names>
</name><name>
<surname>Wang</surname>
<given-names>SI</given-names>
</name><name>
<surname>Puc</surname>
<given-names>J</given-names>
</name><name>
<surname>Miliaresis</surname>
<given-names>C</given-names>
</name><name>
<surname>Rodgers</surname>
<given-names>L</given-names>
</name><name>
<surname>McCombie</surname>
<given-names>R</given-names>
</name><name>
<surname>Bigner</surname>
<given-names>SH</given-names>
</name><name>
<surname>Giovanella</surname>
<given-names>BC</given-names>
</name><name>
<surname>Ittmann</surname>
<given-names>M</given-names>
</name><name>
<surname>Tycko</surname>
<given-names>B</given-names>
</name><name>
<surname>Hibshoosh</surname>
<given-names>H</given-names>
</name><name>
<surname>Wigler</surname>
<given-names>MH</given-names>
</name><name>
<surname>Parsons</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943-7.</source>
<pub-id pub-id-type="pmid">9072974</pub-id>
<pub-id pub-id-type="doi">10.1126/science.275.5308.1943</pub-id>
</element-citation>
    </ref>
    <ref id="B9"><label>9</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Mutter</surname>
<given-names>GL</given-names>
</name><name>
<surname>Lin</surname>
<given-names>MC</given-names>
</name><name>
<surname>Fitzgerald</surname>
<given-names>JT</given-names>
</name><name>
<surname>Kum</surname>
<given-names>JB</given-names>
</name><name>
<surname>Baak</surname>
<given-names>JP</given-names>
</name><name>
<surname>Lees</surname>
<given-names>JA</given-names>
</name><name>
<surname>Weng</surname>
<given-names>LP</given-names>
</name><name>
<surname>Eng</surname>
<given-names>C</given-names>
</name>
</person-group>
<source>Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000 Jun 7;92(11):924-30.</source>
<pub-id pub-id-type="pmid">10841828</pub-id>
<pub-id pub-id-type="doi">10.1093/jnci/92.11.924</pub-id>
</element-citation>
    </ref>
    <ref id="B10"><label>10</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Tian</surname>
<given-names>Y</given-names>
</name><name>
<surname>Li</surname>
<given-names>H</given-names>
</name><name>
<surname>Qiu</surname>
<given-names>T</given-names>
</name><name>
<surname>Dai</surname>
<given-names>J</given-names>
</name><name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name><name>
<surname>Chen</surname>
<given-names>J</given-names>
</name><name>
<surname>Cai</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation. Aging Cell. 2019 Feb;18(1):e12858.</source>
<pub-id pub-id-type="pmid">30548445</pub-id>
<pub-id pub-id-type="pmcid">PMC 6351835</pub-id>
<pub-id pub-id-type="doi">10.1111/acel.12858</pub-id>
</element-citation>
    </ref>
    <ref id="B11"><label>11</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Chen</surname>
<given-names>L</given-names>
</name><name>
<surname>Guo</surname>
<given-names>D</given-names>
</name>
</person-group>
<source>The functions of tumor suppressor PTEN in innate and adaptive immunity. Cell Mol Immunol. 2017 Jul;14(7):581-589.</source>
<pub-id pub-id-type="pmid">28603282</pub-id>
<pub-id pub-id-type="pmcid">PMC 5520418</pub-id>
<pub-id pub-id-type="doi">10.1038/cmi.2017.30</pub-id>
</element-citation>
    </ref>
    <ref id="B12"><label>12</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Rao K</surname>
<given-names>B</given-names>
</name><name>
<surname>Malathi</surname>
<given-names>N</given-names>
</name><name>
<surname>Narashiman</surname>
<given-names>S</given-names>
</name><name>
<surname>Rajan</surname>
<given-names>ST</given-names>
</name>
</person-group>
<source>Evaluation of myofibroblasts by expression of alpha smooth muscle actin: a marker in fibrosis, dysplasia and carcinoma. J Clin Diagn Res. 2014 Apr;8(4):ZC14-7.</source>
<pub-id pub-id-type="pmid">24959509</pub-id>
<pub-id pub-id-type="pmcid">PMC 4064839</pub-id>
<pub-id pub-id-type="doi">10.7860/JCDR/2014/7820.4231</pub-id>
</element-citation>
    </ref>
    <ref id="B13"><label>13</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Angadi</surname>
<given-names>PV</given-names>
</name><name>
<surname>Kale</surname>
<given-names>AD</given-names>
</name><name>
<surname>Hallikerimath</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>Evaluation of myofibroblasts in oral submucous fibrosis: correlation with disease severity. J Oral Pathol Med. 2011 Mar;40(3):208-13.</source>
<pub-id pub-id-type="pmid">21198872</pub-id>
<pub-id pub-id-type="doi">10.1111/j.1600-0714.2010.00995.x</pub-id>
</element-citation>
    </ref>
    <ref id="B14"><label>14</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Miyoshi</surname>
<given-names>K</given-names>
</name><name>
<surname>Yanagi</surname>
<given-names>S</given-names>
</name><name>
<surname>Kawahara</surname>
<given-names>K</given-names>
</name><name>
<surname>Nishio</surname>
<given-names>M</given-names>
</name><name>
<surname>Tsubouchi</surname>
<given-names>H</given-names>
</name><name>
<surname>Imazu</surname>
<given-names>Y</given-names>
</name><name>
<surname>Koshida</surname>
<given-names>R</given-names>
</name><name>
<surname>Matsumoto</surname>
<given-names>N</given-names>
</name><name>
<surname>Taguchi</surname>
<given-names>A</given-names>
</name><name>
<surname>Yamashita</surname>
<given-names>S</given-names>
</name><name>
<surname>Suzuki</surname>
<given-names>A</given-names>
</name><name>
<surname>Nakazato</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>Epithelial Pten controls acute lung injury and fibrosis by regulating alveolar epithelial cell integrity. Am J Respir Crit Care Med. 2013 Feb 1;187(3):262-75.</source>
<pub-id pub-id-type="pmid">23239155</pub-id>
<pub-id pub-id-type="doi">10.1164/rccm.201205-0851OC</pub-id>
</element-citation>
    </ref>
    <ref id="B15"><label>15</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>White</surname>
<given-names>ES</given-names>
</name><name>
<surname>Atrasz</surname>
<given-names>RG</given-names>
</name><name>
<surname>Hu</surname>
<given-names>B</given-names>
</name><name>
<surname>Phan</surname>
<given-names>SH</given-names>
</name><name>
<surname>Stambolic</surname>
<given-names>V</given-names>
</name><name>
<surname>Mak</surname>
<given-names>TW</given-names>
</name><name>
<surname>Hogaboam</surname>
<given-names>CM</given-names>
</name><name>
<surname>Flaherty</surname>
<given-names>KR</given-names>
</name><name>
<surname>Martinez</surname>
<given-names>FJ</given-names>
</name><name>
<surname>Kontos</surname>
<given-names>CD</given-names>
</name><name>
<surname>Toews</surname>
<given-names>GB</given-names>
</name>
</person-group>
<source>Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med. 2006 Jan 1;173(1):112-21.</source>
<pub-id pub-id-type="pmid">16179636</pub-id>
<pub-id pub-id-type="pmcid">PMC 1434700</pub-id>
<pub-id pub-id-type="doi">10.1164/rccm.200507-1058OC</pub-id>
</element-citation>
    </ref>
    <ref id="B16"><label>16</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Gupta</surname>
<given-names>K</given-names>
</name><name>
<surname>Metgud</surname>
<given-names>R</given-names>
</name><name>
<surname>Gupta</surname>
<given-names>J</given-names>
</name>
</person-group>
<source>Evaluation of stromal myofibroblasts in oral leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma--an immunohistochemical study. J Cancer Res Ther. 2015 Oct-Dec;11(4):893-8.</source>
<pub-id pub-id-type="pmid">26881537</pub-id>
<pub-id pub-id-type="doi">10.4103/0973-1482.147700</pub-id>
</element-citation>
    </ref>
    <ref id="B17"><label>17</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>More</surname>
<given-names>CB</given-names>
</name><name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name><name>
<surname>Joshi</surname>
<given-names>J</given-names>
</name><name>
<surname>Varma</surname>
<given-names>SN</given-names>
</name>
</person-group>
<source>Classification system for oral submucous fibrosis. J Ind Aca Oral Med Radiol. 2012 Jan; 24(1): 24-29. URL: </source>
<comment><ext-link ext-link-type="uri" xlink:href="https://www.jiaomr.in">https://www.jiaomr.in</ext-link></comment>
<pub-id pub-id-type="doi">10.5037/jomr.2011.2305</pub-id>
</element-citation>
    </ref>
    <ref id="B18"><label>18</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Lydiatt</surname>
<given-names>WM</given-names>
</name><name>
<surname>Patel</surname>
<given-names>SG</given-names>
</name><name>
<surname>O'Sullivan</surname>
<given-names>B</given-names>
</name><name>
<surname>Brandwein</surname>
<given-names>MS</given-names>
</name><name>
<surname>Ridge</surname>
<given-names>JA</given-names>
</name><name>
<surname>Migliacci</surname>
<given-names>JC</given-names>
</name><name>
<surname>Loomis</surname>
<given-names>AM</given-names>
</name><name>
<surname>Shah</surname>
<given-names>JP</given-names>
</name>
</person-group>
<source>Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Mar;67(2):122-137.</source>
<pub-id pub-id-type="pmid">28128848</pub-id>
<pub-id pub-id-type="doi">10.3322/caac.21389</pub-id>
</element-citation>
    </ref>
    <ref id="B19"><label>19</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Rooban</surname>
<given-names>T</given-names>
</name><name>
<surname>Saraswathi</surname>
<given-names>TR</given-names>
</name><name>
<surname>Al Zainab</surname>
<given-names>FH</given-names>
</name><name>
<surname>Devi</surname>
<given-names>U</given-names>
</name><name>
<surname>Eligabeth</surname>
<given-names>J</given-names>
</name><name>
<surname>Ranganathan</surname>
<given-names>K</given-names>
</name>
</person-group>
<source>A light microscopic study of fibrosis involving muscle in oral submucous fibrosis. Indian J Dent Res. 2005 Oct-Dec;16(4):131-4.</source>
<pub-id pub-id-type="pmid">16761704</pub-id>
<pub-id pub-id-type="doi">10.4103/0970-9290.29909</pub-id>
</element-citation>
    </ref>
    <ref id="B20"><label>20</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Neena</surname>
<given-names>D</given-names>
</name><name>
<surname>Shah</surname>
<given-names>S</given-names>
</name><name>
<surname>Keyuri</surname>
<given-names>P</given-names>
</name><name>
<surname>Munira</surname>
<given-names>J</given-names>
</name>
</person-group>
<source>Histological grading of oral cancer: A comparison of different systems and their relation to lymph node metastasis. Nat J Commun Med. 2011 Jan; 2(1): 136-42. URL: </source><comment><ext-link ext-link-type="uri" xlink:href="http://njcmindia.org/uploads/2-1_136-142.pdf">http://njcmindia.org/uploads/2-1_136-142.pdf</ext-link></comment>
</element-citation>
    </ref>
    <ref id="B21"><label>21</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Angadi</surname>
<given-names>PV</given-names>
</name><name>
<surname>Krishnapillai</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>Evaluation of PTEN immunoexpression in oral submucous fibrosis: role in pathogenesis and malignant transformation. Head Neck Pathol. 2012 Sep;6(3):314-21.</source>
<pub-id pub-id-type="pmid">22392409</pub-id>
<pub-id pub-id-type="pmcid">PMC 3422583</pub-id>
<pub-id pub-id-type="doi">10.1007/s12105-012-0341-z</pub-id>
</element-citation>
    </ref>
    <ref id="B22"><label>22</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Roa</surname>
<given-names>I</given-names>
</name><name>
<surname>de Toro</surname>
<given-names>G</given-names>
</name><name>
<surname>Fernández</surname>
<given-names>F</given-names>
</name><name>
<surname>Game</surname>
<given-names>A</given-names>
</name><name>
<surname>Muñoz</surname>
<given-names>S</given-names>
</name><name>
<surname>de Aretxabala</surname>
<given-names>X</given-names>
</name><name>
<surname>Javle</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol. 2015 Aug 21;10:148.</source>
<pub-id pub-id-type="pmid">26294099</pub-id>
<pub-id pub-id-type="pmcid">PMC 4546176</pub-id>
<pub-id pub-id-type="doi">10.1186/s13000-015-0381-2</pub-id>
</element-citation>
    </ref>
    <ref id="B23"><label>23</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Yamada</surname>
<given-names>KM</given-names>
</name><name>
<surname>Araki</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci. 2001 Jul;114(Pt 13):2375-82.</source>
<pub-id pub-id-type="pmid">11559746</pub-id>
</element-citation>
    </ref>
    <ref id="B24"><label>24</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Squarize</surname>
<given-names>CH</given-names>
</name><name>
<surname>Castilho</surname>
<given-names>RM</given-names>
</name><name>
<surname>Abrahao</surname>
<given-names>AC</given-names>
</name><name>
<surname>Molinolo</surname>
<given-names>A</given-names>
</name><name>
<surname>Lingen</surname>
<given-names>MW</given-names>
</name><name>
<surname>Gutkind</surname>
<given-names>JS</given-names>
</name>
</person-group>
<source>PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 2013 May;15(5):461-71.</source>
<pub-id pub-id-type="pmid">23633918</pub-id>
<pub-id pub-id-type="pmcid">PMC 3638349</pub-id>
<pub-id pub-id-type="doi">10.1593/neo.121024</pub-id>
</element-citation>
    </ref>
    <ref id="B25"><label>25</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Miyahara</surname>
<given-names>LAN</given-names>
</name><name>
<surname>Pontes</surname>
<given-names>FSC</given-names>
</name><name>
<surname>Burbano</surname>
<given-names>RMR</given-names>
</name><name>
<surname>Conte Neto</surname>
<given-names>N</given-names>
</name><name>
<surname>Guimarães</surname>
<given-names>DM</given-names>
</name><name>
<surname>Fonseca</surname>
<given-names>FP</given-names>
</name><name>
<surname>Pontes</surname>
<given-names>HAR</given-names>
</name>
</person-group>
<source>PTEN allelic loss is an important mechanism in the late stage of development of oral leucoplakia into oral squamous cell carcinoma. Histopathology. 2018 Jan;72(2):330-338.</source>
<pub-id pub-id-type="pmid">28858374</pub-id>
<pub-id pub-id-type="doi">10.1111/his.13381</pub-id>
</element-citation>
    </ref>
    <ref id="B26"><label>26</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Afroz</surname>
<given-names>N</given-names>
</name><name>
<surname>Hasan</surname>
<given-names>SA</given-names>
</name><name>
<surname>Naseem</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>Oral Submucous Fibrosis a Distressing Disease with Malignant Potential. Ind J Comm Med. 2006 Oct-Dec; 31(4): 270. URL: </source>
<comment><ext-link ext-link-type="uri" xlink:href="https://www.ijcm.org.in">https://www.ijcm.org.in</ext-link></comment>
<pub-id pub-id-type="doi">10.5037/jomr.2011.2305</pub-id>
</element-citation>
    </ref>
    <ref id="B27"><label>27</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Angadi</surname>
<given-names>PV</given-names>
</name><name>
<surname>Rekha</surname>
<given-names>KP</given-names>
</name>
</person-group>
<source>Oral submucous fibrosis: a clinicopathologic review of 205 cases in Indians. Oral Maxillofac Surg. 2011 Mar;15(1):15-9.</source>
<pub-id pub-id-type="pmid">20414694</pub-id>
<pub-id pub-id-type="doi">10.1007/s10006-010-0225-x</pub-id>
</element-citation>
    </ref>
    <ref id="B28"><label>28</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Siriwardena</surname>
<given-names>BSMS</given-names>
</name><name>
<surname>Jayawardena</surname>
<given-names>KLTD</given-names>
</name><name>
<surname>Senarath</surname>
<given-names>NH</given-names>
</name><name>
<surname>Tilakaratne</surname>
<given-names>WM</given-names>
</name>
</person-group>
<source>An Evaluation of Clinical and Histopathological Aspects of Patients with Oral Submucous Fibrosis in the Background of Oral Squamous Cell Carcinoma. Biomed Res Int. 2018 Oct 9;2018:4154165.</source>
<pub-id pub-id-type="pmid">30402477</pub-id>
<pub-id pub-id-type="pmcid">PMC 6198553</pub-id>
<pub-id pub-id-type="doi">10.1155/2018/4154165</pub-id>
</element-citation>
    </ref>
    <ref id="B29"><label>29</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Acharya</surname>
<given-names>S</given-names>
</name><name>
<surname>Rahman</surname>
<given-names>S</given-names>
</name><name>
<surname>Hallikeri</surname>
<given-names>K</given-names>
</name>
</person-group>
<source>A retrospective study of clinicopathological features of oral squamous cell carcinoma with and without oral submucous fibrosis. J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):162.</source>
<pub-id pub-id-type="pmid">31110444</pub-id>
<pub-id pub-id-type="pmcid">PMC 6503806</pub-id>
</element-citation>
    </ref>
    <ref id="B30"><label>30</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Guo</surname>
<given-names>F</given-names>
</name><name>
<surname>Jian</surname>
<given-names>XC</given-names>
</name><name>
<surname>Zhou</surname>
<given-names>SH</given-names>
</name><name>
<surname>Li</surname>
<given-names>N</given-names>
</name><name>
<surname>Hu</surname>
<given-names>YJ</given-names>
</name><name>
<surname>Tang</surname>
<given-names>ZG</given-names>
</name>
</person-group>
<source>[A retrospective study of oral squamous cell carcinomas originated from oral submucous fibrosis]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2011 Aug;46(8):494-7. Chinese.</source>
<pub-id pub-id-type="pmid">22169748</pub-id>
</element-citation>
    </ref>
    <ref id="B31"><label>31</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Payne</surname>
<given-names>SR</given-names>
</name><name>
<surname>Kemp</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<source>Tumor suppressor genetics. Carcinogenesis. 2005 Dec;26(12):2031-45.</source>
<pub-id pub-id-type="pmid">16150895</pub-id>
<pub-id pub-id-type="doi">10.1093/carcin/bgi223</pub-id>
</element-citation>
    </ref>
    <ref id="B32"><label>32</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Thomas</surname>
<given-names>S</given-names>
</name><name>
<surname>Balan</surname>
<given-names>A</given-names>
</name><name>
<surname>Balaram</surname>
<given-names>P</given-names>
</name>
</person-group>
<source>The expression of retinoblastoma tumor suppressor protein in oral cancers and precancers: A clinicopathological study. Dent Res J (Isfahan). 2015 Jul-Aug;12(4):307-14.</source>
<pub-id pub-id-type="pmid">26288619</pub-id>
<pub-id pub-id-type="pmcid">PMC 4533187</pub-id>
<pub-id pub-id-type="doi">10.4103/1735-3327.161427</pub-id>
</element-citation>
    </ref>
    <ref id="B33"><label>33</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Win</surname>
<given-names>SS</given-names>
</name><name>
<surname>Nishioka</surname>
<given-names>M</given-names>
</name><name>
<surname>Myint</surname>
<given-names>B</given-names>
</name><name>
<surname>Takagi</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>Assessment of p53 protein expression in leukoplakia, oral submucous fibrosis and oral lichen planus in Myanmar patients. Oral Med Pathol. 2005 Mar 25;10(1):15-21.</source>
<pub-id pub-id-type="doi">10.3353/omp.10.15</pub-id>
</element-citation>
    </ref>
    <ref id="B34"><label>34</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Shen</surname>
<given-names>WH</given-names>
</name><name>
<surname>Balajee</surname>
<given-names>AS</given-names>
</name><name>
<surname>Wang</surname>
<given-names>J</given-names>
</name><name>
<surname>Wu</surname>
<given-names>H</given-names>
</name><name>
<surname>Eng</surname>
<given-names>C</given-names>
</name><name>
<surname>Pandolfi</surname>
<given-names>PP</given-names>
</name><name>
<surname>Yin</surname>
<given-names>Y</given-names>
</name>
</person-group>
<source>Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007 Jan 12;128(1):157-70.</source>
<pub-id pub-id-type="pmid">17218262</pub-id>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.11.042</pub-id>
</element-citation>
    </ref>
    <ref id="B35"><label>35</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Jasphin</surname>
<given-names>SS</given-names>
</name><name>
<surname>Desai</surname>
<given-names>D</given-names>
</name><name>
<surname>Pandit</surname>
<given-names>S</given-names>
</name><name>
<surname>Gonsalves</surname>
<given-names>NM</given-names>
</name><name>
<surname>Nayak</surname>
<given-names>PB</given-names>
</name><name>
<surname>Iype</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>Immunohistochemical expression of phosphatase and tensin homolog in histologic gradings of oral squamous cell carcinoma. Contemp Clin Dent. 2016 Oct-Dec;7(4): 524-528.</source>
<pub-id pub-id-type="pmid">27994422</pub-id>
<pub-id pub-id-type="pmcid">PMC 5141669</pub-id>
<pub-id pub-id-type="doi">10.4103/0976-237X.194111</pub-id>
</element-citation>
    </ref>
    <ref id="B36"><label>36</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Chen</surname>
<given-names>CY</given-names>
</name><name>
<surname>Chen</surname>
<given-names>J</given-names>
</name><name>
<surname>He</surname>
<given-names>L</given-names>
</name><name>
<surname>Stiles</surname>
<given-names>BL</given-names>
</name>
</person-group>
<source>PTEN: Tumor Suppressor and Metabolic Regulator. Front Endocrinol (Lausanne). 2018 Jul 9;9:338.</source>
<pub-id pub-id-type="pmid">30038596</pub-id>
<pub-id pub-id-type="pmcid">PMC 6046409</pub-id>
<pub-id pub-id-type="doi">10.3389/fendo.2018.00338</pub-id>
</element-citation>
    </ref>
    <ref id="B37"><label>37</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Tamguney</surname>
<given-names>T</given-names>
</name><name>
<surname>Stokoe</surname>
<given-names>D</given-names>
</name>
</person-group>
<source>New insights into PTEN. J Cell Sci. 2007 Dec 1;120(Pt 23):4071-9.</source>
<pub-id pub-id-type="pmid">18032782</pub-id>
<pub-id pub-id-type="doi">10.1242/jcs.015230</pub-id>
</element-citation>
    </ref>
    <ref id="B38"><label>38</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Sulis</surname>
<given-names>ML</given-names>
</name><name>
<surname>Parsons</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>PTEN: from pathology to biology. Trends Cell Biol. 2003 Sep;13(9):478-83.</source>
<pub-id pub-id-type="pmid">12946627</pub-id>
<pub-id pub-id-type="doi">10.1016/S0962-8924(03)00175-2</pub-id>
</element-citation>
    </ref>
    <ref id="B39"><label>39</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Kurasawa</surname>
<given-names>Y</given-names>
</name><name>
<surname>Shiiba</surname>
<given-names>M</given-names>
</name><name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name><name>
<surname>Fushimi</surname>
<given-names>K</given-names>
</name><name>
<surname>Ishigami</surname>
<given-names>T</given-names>
</name><name>
<surname>Bukawa</surname>
<given-names>H</given-names>
</name><name>
<surname>Yokoe</surname>
<given-names>H</given-names>
</name><name>
<surname>Uzawa</surname>
<given-names>K</given-names>
</name><name>
<surname>Tanzawa</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>PTEN expression and methylation status in oral squamous cell carcinoma. Oncol Rep. 2008 Jun;19(6):1429-34.</source>
<pub-id pub-id-type="pmid">18497947</pub-id>
</element-citation>
    </ref>
    <ref id="B40"><label>40</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Mavros</surname>
<given-names>A</given-names>
</name><name>
<surname>Hahn</surname>
<given-names>M</given-names>
</name><name>
<surname>Wieland</surname>
<given-names>I</given-names>
</name><name>
<surname>Koy</surname>
<given-names>S</given-names>
</name><name>
<surname>Koufaki</surname>
<given-names>ON</given-names>
</name><name>
<surname>Strelocke</surname>
<given-names>K</given-names>
</name><name>
<surname>Koch</surname>
<given-names>R</given-names>
</name><name>
<surname>Haroske</surname>
<given-names>G</given-names>
</name><name>
<surname>Schackert</surname>
<given-names>HK</given-names>
</name><name>
<surname>Eckelt</surname>
<given-names>U</given-names>
</name>
</person-group>
<source>Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity. J Oral Pathol Med. 2002 May;31(5):270-6.</source>
<pub-id pub-id-type="pmid">12110043</pub-id>
<pub-id pub-id-type="doi">10.1034/j.1600-0714.2002.310504.x</pub-id>
</element-citation>
    </ref>
    <ref id="B41"><label>41</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Salmani</surname>
<given-names>H</given-names>
</name><name>
<surname>Hosseini</surname>
<given-names>A</given-names>
</name><name>
<surname>Azarnezhad</surname>
<given-names>A</given-names>
</name><name>
<surname>Ahmad</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>PTEN and p53 gene expressions in breast cancer specimens and their clinicopathological significance. Middle East J Cancer. 2018 Apr; 9(2):105-111.</source>
<pub-id pub-id-type="doi">10.30476/mejc.2018.42112</pub-id>
</element-citation>
    </ref>
    <ref id="B42"><label>42</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Trotman</surname>
<given-names>LC</given-names>
</name><name>
<surname>Pandolfi</surname>
<given-names>PP</given-names>
</name>
</person-group>
<source>PTEN and p53: who will get the upper hand? Cancer Cell. 2003 Feb;3(2):97-9.</source>
<pub-id pub-id-type="pmid">12620402</pub-id>
<pub-id pub-id-type="doi">10.1016/S1535-6108(03)00022-9</pub-id>
</element-citation>
    </ref>
    <ref id="B43"><label>43</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Minami</surname>
<given-names>A</given-names>
</name><name>
<surname>Murai</surname>
<given-names>T</given-names>
</name><name>
<surname>Nakanishi</surname>
<given-names>A</given-names>
</name><name>
<surname>Kitagishi</surname>
<given-names>Y</given-names>
</name><name>
<surname>Ichimura</surname>
<given-names>M</given-names>
</name><name>
<surname>Matsuda</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>Cell Cycle Regulation via the p53, PTEN, and BRCA1 Tumor Suppressors. In: Dmitry Bulgin, editors. New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis. IntechOpen; 2016.</source>
<pub-id pub-id-type="doi">10.5772/61116</pub-id>
</element-citation>
    </ref>
    <ref id="B44"><label>44</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Nakanishi</surname>
<given-names>A</given-names>
</name><name>
<surname>Kitagishi</surname>
<given-names>Y</given-names>
</name><name>
<surname>Ogura</surname>
<given-names>Y</given-names>
</name><name>
<surname>Matsuda</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review). Int J Oncol. 2014 Jun;44(6):1813-9.</source>
<pub-id pub-id-type="pmid">24718924</pub-id>
<pub-id pub-id-type="doi">10.3892/ijo.2014.2377</pub-id>
</element-citation>
    </ref>
    <ref id="B45"><label>45</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Puzio-Kuter</surname>
<given-names>AM</given-names>
</name><name>
<surname>Laddha</surname>
<given-names>SV</given-names>
</name><name>
<surname>Castillo-Martin</surname>
<given-names>M</given-names>
</name><name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name><name>
<surname>Cordon-Cardo</surname>
<given-names>C</given-names>
</name><name>
<surname>Chan</surname>
<given-names>CS</given-names>
</name><name>
<surname>Levine</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<source>Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma. Cell Death Differ. 2015 Nov;22(11): 1785-91.</source>
<pub-id pub-id-type="pmid">25822339</pub-id>
<pub-id pub-id-type="pmcid">PMC 4648325</pub-id>
<pub-id pub-id-type="doi">10.1038/cdd.2015.27</pub-id>
</element-citation>
    </ref>
    <ref id="B46"><label>46</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Hinz</surname>
<given-names>B</given-names>
</name><name>
<surname>Phan</surname>
<given-names>SH</given-names>
</name><name>
<surname>Thannickal</surname>
<given-names>VJ</given-names>
</name><name>
<surname>Galli</surname>
<given-names>A</given-names>
</name><name>
<surname>Bochaton-Piallat</surname>
<given-names>ML</given-names>
</name><name>
<surname>Gabbiani</surname>
<given-names>G</given-names>
</name>
</person-group>
<source>The myofibroblast: one function, multiple origins. Am J Pathol. 2007 Jun;170(6):1807-16.</source>
<pub-id pub-id-type="pmid">17525249</pub-id>
<pub-id pub-id-type="pmcid">PMC 1899462</pub-id>
<pub-id pub-id-type="doi">10.2353/ajpath.2007.070112</pub-id>
</element-citation>
    </ref>
    <ref id="B47"><label>47</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Desmoulière</surname>
<given-names>A</given-names>
</name><name>
<surname>Guyot</surname>
<given-names>C</given-names>
</name><name>
<surname>Gabbiani</surname>
<given-names>G</given-names>
</name>
</person-group>
<source>The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol. 2004;48(5-6):509-17.</source>
<pub-id pub-id-type="pmid">15349825</pub-id>
<pub-id pub-id-type="doi">10.1387/ijdb.041802ad</pub-id>
</element-citation>
    </ref>
    <ref id="B48"><label>48</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Milella</surname>
<given-names>M</given-names>
</name><name>
<surname>Falcone</surname>
<given-names>I</given-names>
</name><name>
<surname>Conciatori</surname>
<given-names>F</given-names>
</name><name>
<surname>Cesta Incani</surname>
<given-names>U</given-names>
</name><name>
<surname>Del Curatolo</surname>
<given-names>A</given-names>
</name><name>
<surname>Inzerilli</surname>
<given-names>N</given-names>
</name><name>
<surname>Nuzzo</surname>
<given-names>CM</given-names>
</name><name>
<surname>Vaccaro</surname>
<given-names>V</given-names>
</name><name>
<surname>Vari</surname>
<given-names>S</given-names>
</name><name>
<surname>Cognetti</surname>
<given-names>F</given-names>
</name><name>
<surname>Ciuffreda</surname>
<given-names>L</given-names>
</name>
</person-group>
<source>PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol. 2015 Feb 16;5:24.</source>
<pub-id pub-id-type="pmid">25763354</pub-id>
<pub-id pub-id-type="pmcid">PMC 4329810</pub-id>
<pub-id pub-id-type="doi">10.3389/fonc.2015.00024</pub-id>
</element-citation>
    </ref>
    <ref id="B49"><label>49</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Baak</surname>
<given-names>JP</given-names>
</name><name>
<surname>Van Diermen</surname>
<given-names>B</given-names>
</name><name>
<surname>Steinbakk</surname>
<given-names>A</given-names>
</name><name>
<surname>Janssen</surname>
<given-names>E</given-names>
</name><name>
<surname>Skaland</surname>
<given-names>I</given-names>
</name><name>
<surname>Mutter</surname>
<given-names>GL</given-names>
</name><name>
<surname>Fiane</surname>
<given-names>B</given-names>
</name><name>
<surname>Løvslett</surname>
<given-names>K</given-names>
</name>
</person-group>
<source>Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum Pathol. 2005 May;36(5):555-61.</source>
<pub-id pub-id-type="pmid">15948123</pub-id>
<pub-id pub-id-type="doi">10.1016/j.humpath.2005.02.018</pub-id>
</element-citation>
    </ref>
    <ref id="B50"><label>50</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Xie</surname>
<given-names>B</given-names>
</name><name>
<surname>Zheng</surname>
<given-names>G</given-names>
</name><name>
<surname>Li</surname>
<given-names>H</given-names>
</name><name>
<surname>Yao</surname>
<given-names>X</given-names>
</name><name>
<surname>Hong</surname>
<given-names>R</given-names>
</name><name>
<surname>Li</surname>
<given-names>R</given-names>
</name><name>
<surname>Yue</surname>
<given-names>W</given-names>
</name><name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
</person-group>
<source>Effects of the tumor suppressor PTEN on the pathogenesis of idiopathic pulmonary fibrosis in Chinese patients. Mol Med Rep. 2016 Mar;13(3):2715-23.</source>
<pub-id pub-id-type="pmid">26846484</pub-id>
<pub-id pub-id-type="doi">10.3892/mmr.2016.4852</pub-id>
</element-citation>
    </ref>
    <ref id="B51"><label>51</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Alka</surname>
<given-names>HH</given-names>
</name><name>
<surname>Prajakta</surname>
<given-names>ZR</given-names>
</name><name>
<surname>Minal</surname>
<given-names>CS</given-names>
</name><name>
<surname>Madhuri</surname>
<given-names>GN</given-names>
</name><name>
<surname>Swati</surname>
<given-names>P</given-names>
</name><name>
<surname>Aakruti</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>Immunohistochemical analysis of tumor-associated stroma in oral squamous cell carcinoma with and without preexisting oral submucous fibrosis. J Datta Meghe Inst Med Sci Univ. 2017 Jul;12(3):170-76.</source>
<pub-id pub-id-type="doi">10.4103/jdmimsu.jdmimsu_8_17</pub-id>
</element-citation>
    </ref>
    <ref id="B52"><label>52</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Mohiuddin</surname>
<given-names>S</given-names>
</name><name>
<surname>Fatima</surname>
<given-names>N</given-names>
</name><name>
<surname>Hosein</surname>
<given-names>S</given-names>
</name><name>
<surname>Fatima</surname>
<given-names>N</given-names>
</name>
</person-group>
<source>High risk of malignant transformation of oral submucous fibrosis in Pakistani females: A potential national disaster. J Pak Med Assoc. 2016 Nov;66(11):1362-1366.</source>
<pub-id pub-id-type="pmid">27812049</pub-id>
</element-citation>
    </ref>
    <ref id="B53"><label>53</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Kellermann</surname>
<given-names>MG</given-names>
</name><name>
<surname>Sobral</surname>
<given-names>LM</given-names>
</name><name>
<surname>da Silva</surname>
<given-names>SD</given-names>
</name><name>
<surname>Zecchin</surname>
<given-names>KG</given-names>
</name><name>
<surname>Graner</surname>
<given-names>E</given-names>
</name><name>
<surname>Lopes</surname>
<given-names>MA</given-names>
</name><name>
<surname>Kowalski</surname>
<given-names>LP</given-names>
</name><name>
<surname>Coletta</surname>
<given-names>RD</given-names>
</name>
</person-group>
<source>Mutual paracrine effects of oral squamous cell carcinoma cells and normal oral fibroblasts: induction of fibroblast to myofibroblast transdifferentiation and modulation of tumor cell proliferation. Oral Oncol. 2008 May;44(5):509-17.</source>
<pub-id pub-id-type="pmid">17826300</pub-id>
<pub-id pub-id-type="doi">10.1016/j.oraloncology.2007.07.001</pub-id>
</element-citation>
    </ref>
    <ref id="B54"><label>54</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Bagalad</surname>
<given-names>BS</given-names>
</name><name>
<surname>Mohan Kumar</surname>
<given-names>KP</given-names>
</name><name>
<surname>Puneeth</surname>
<given-names>HK</given-names>
</name>
</person-group>
<source>Myofibroblasts: Master of disguise. J Oral Maxillofac Pathol. 2017 Sep-Dec;21(3):462-463.</source>
<pub-id pub-id-type="pmid">29391737</pub-id>
<pub-id pub-id-type="pmcid">PMC 5763885</pub-id>
<pub-id pub-id-type="doi">10.4103/jomfp.JOMFP_146_15</pub-id>
</element-citation>
    </ref>
    <ref id="B55"><label>55</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Jayaraj</surname>
<given-names>G</given-names>
</name><name>
<surname>Sherlin</surname>
<given-names>HJ</given-names>
</name><name>
<surname>Ramani</surname>
<given-names>P</given-names>
</name><name>
<surname>Premkumar</surname>
<given-names>P</given-names>
</name><name>
<surname>Natesan</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>Stromal myofibroblasts in oral squamous cell carcinoma and potentially malignant disorders. Indian J Cancer. 2015 Jan-Mar;52(1):87-92.</source>
<pub-id pub-id-type="pmid">26837985</pub-id>
<pub-id pub-id-type="doi">10.4103/0019-509X.175580</pub-id>
</element-citation>
    </ref>
    <ref id="B56"><label>56</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Chaudhari</surname>
<given-names>RB</given-names>
</name>
</person-group>
<source>Myofibroblasts: Functions, evolution, origins, and the role in disease. SRM J Res Dent Sci. 2015 Nov;6(4):234-9.</source>
<pub-id pub-id-type="doi">10.4103/0976-433X.156219</pub-id>
</element-citation>
    </ref>
    <ref id="B57"><label>57</label>
      <element-citation>
        <person-group person-group-type="author">
          <name>
<surname>Micallef</surname>
<given-names>L</given-names>
</name><name>
<surname>Vedrenne</surname>
<given-names>N</given-names>
</name><name>
<surname>Billet</surname>
<given-names>F</given-names>
</name><name>
<surname>Coulomb</surname>
<given-names>B</given-names>
</name><name>
<surname>Darby</surname>
<given-names>IA</given-names>
</name><name>
<surname>Desmoulière</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1):S5.</source>
<pub-id pub-id-type="pmid">23259712</pub-id>
<pub-id pub-id-type="pmcid">PMC 3368789</pub-id>
<pub-id pub-id-type="doi">10.1186/1755-1536-5-S1-S5</pub-id>
</element-citation>
    </ref>
    </ref-list>
</back>
</article>